Women’s Wellness: Hormones, Menopause, and Heart Health

Why It Matters

Understanding menopause as a major, modifiable cardiovascular risk factor reshapes prevention strategies, driving better outcomes for women and creating new opportunities for clinicians, insurers, and pharma to address a growing public‑health challenge.

Key Takeaways

• Cardiovascular disease remains leading cause of death in women.
• Menopause increases heart risk via estrogen loss and visceral fat.
• Hormone therapy misconceptions stem from outdated Women’s Health Initiative data.
• Early or surgical menopause amplifies cardiovascular risk across lifespan.
• Integrated endocrine‑cardiac care essential for prevention and treatment.

Summary

The NYU Center for Prevention of Cardiovascular Disease hosted a webinar focusing on the intersection of hormones, menopause, and heart health, featuring endocrinology expert Dr. Priya Jenani. The session highlighted that cardiovascular disease is the top killer of women, yet risk is often underestimated by both patients and clinicians, especially during hormonal transitions. Key insights included the dramatic rise in cardiovascular risk after menopause due to estrogen decline, which drives visceral fat accumulation, loss of lean muscle, insulin resistance, endothelial dysfunction, and adverse lipid changes. Traditional risk factors such as smoking, hypertension, and obesity compound these effects, while pregnancy complications, PCOS, and early or surgical menopause further elevate danger. The discussion also debunked lingering myths about hormone replacement therapy that originated from the Women’s Health Initiative, noting newer data and AHA guidance that recognize menopause as an independent risk factor. Dr. Jenani cited striking statistics: roughly 6,000 U.S. women enter menopause daily, and by 2030 an estimated 1.2 billion women worldwide will be post‑menopausal, spending up to 40 % of their lives in this state. Up to 70 % experience weight gain, predominantly abdominal, and one‑quarter develop irregular heart rhythms linked to sleep disturbances. The 2020 AHA statement and Framingham findings—showing that pre‑menopausal cholesterol and blood pressure can precipitate earlier menopause—underscored the bidirectional nature of endocrine‑cardiac risk. The implications are clear: clinicians must adopt integrated screening that accounts for hormonal history, educate women on the true breadth of menopausal symptoms beyond hot flashes, and consider personalized hormone therapy where appropriate. Health systems and insurers should prioritize preventive programs targeting weight, muscle preservation, and sleep quality to mitigate the looming cardiovascular burden among aging women.

Original Description

What’s the most up-to-date story on women’s hormones and heart health? Does hormone therapy during menopause help or harm your heart? With the FDA’s recent removal of the black box warning on many hormone replacement therapies (HRT), it’s normal to have questions about their safety and impact.

Join NYU Langone endocrinologist Priya Jaisinghani, MD, as she clears up confusion surrounding menopausal hormone therapy, explores its effects on the cardiovascular system, and discusses the benefit–risk balance of starting treatment. NYU Langone cardiologist and webinar moderator Dennis A. Goodman, MD, will lead the live audience Q&A. Invite a friend and be inspired to be a hero for women’s heart health.

Learn more about NYU Langone’s Center for the Prevention of Cardiovascular Disease:

https://nyulangone.org/cvdprevention

Video Chapters

00:00 Introduction and Upcoming Events

03:23 Presentation Outline

03:50 Why Are Menopause and Heart Health So Important?

07:39 Definition of Menopause

09:09 Symptoms of Perimenopause

09:54 Features of Menopause

15:17 Overlap Between the Endocrine and Cardiovascular Systems

17:31 Why Premenopausal Cardiovascular Health Matters

19:26 Insulin Resistance

21:35 Diet and Lifestyle Changes

26:07 Nonhormonal Therapies for Menopause

27:52 Hormone Replacement Therapy

38:16 Menopausal Hormone Therapy vs. Bioidentical Hormone Replacement

39:35 Removal of the Black Box Warning

42:48 Nutrient-Stimulated Hormone Therapies (NuSH)

44:47 How Do We Optimize Multidisciplinary Care?

45:46 Conclusions

47:19 Question and Answer Session